European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

Thermal Evaluation of specific drug delivery with Molecularly imprinted nanoParticles developed against Estrogen Receptor

Description du projet

Un nanosupport de médicament simple mais spécifique

La mortalité associée au cancer du sein dans les pays en développement est plus élevée que dans les pays à revenu élevé. Cela indique que le traitement n’atteint pas les régions financièrement défavorisées. Pour résoudre ce problème, le projet TEMPER financé par l’UE propose de développer des nanosupports de médicaments polymères démontrant une spécificité et une efficacité de ciblage plus élevées sans les effets secondaires courants des médicaments conventionnels. Ces nanosupports seront très polyvalents et pourront être adaptés pour administrer n’importe quel médicament, y compris des antibiotiques contre les infections, ou pour être utilisés à des fins de diagnostic. La simplicité et la rentabilité de l’approche d’administration de médicaments TEMPER garantiront son applicabilité dans les pays en développement.

Objectif

Breast cancer is the most commonly occurring cancer in women with over two million new cases reported in 2018. It is a genetically diverse disease with each type requiring different treatment. In developing countries, the highest amount of female cancer deaths are attributed to breast cancer with substantially lower survival rates compared to the western world. Therefore, the aim of this proposal is to develop polymeric drug nanocarriers that can improve drug efficacy, and thereby have potential to make cancer treatment available to all layers of the population including those living in deprived areas. We will develop high affinity nanoparticles that can selectively bind to certain receptors on the surface of cancer cells. When attached, the nanocarriers will release their cargo (drug compounds) specifically to the tumour and thereby improve drug efficacy and subsequently patient outcome. Furthermore, it will reduce adverse effects of common anti-cancer drugs including nausea, fatigue, hepatitis and high vulnerability to endometrial cancer. The drug delivery is usually monitored with optical techniques but the novelty of this project is to use thermal analysis, which is label-free and simple to use. The polymeric nanocarriers are highly versatile and by changing the composition, we can tailor this platform to other drug compounds or other cancer types. In addition, it has high potential as a diagnostic tool in high-throughput drug testing, customization of cellular therapy, and combating bacterial infections. This project could bring tremendous benefits in cancer treatment particularly in developing countries such as India due to its low-cost and simplicity.

Coordinateur

UNIVERSITY OF NEWCASTLE UPON TYNE
Contribution nette de l'UE
€ 224 933,76
Adresse
KINGS GATE
NE1 7RU Newcastle Upon Tyne
Royaume-Uni

Voir sur la carte

Région
North East (England) Northumberland and Tyne and Wear Tyneside
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
€ 224 933,76